MUDr. Miloš Holánek, Ph.D.
Assistant professor, Comprehensive Cancer Care Department
Total number of publications: 16
2021
-
Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK plus lung cancer in the kidney transplant recipient
International Immunopharmacology, year: 2021, volume: 99, edition: October 2021, DOI
-
Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence
Cancers, year: 2021, volume: 13, edition: 7, DOI
2020
-
Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry
Cancers, year: 2020, volume: 12, edition: 10, DOI
2019
-
Méně časté mutace EGFR v kontextu léčby nemalobuněčného karcinomu plic
Klinická onkologie, year: 2019, volume: 32, edition: Supplementum 3, DOI
2007
-
Importance of Monitoring the Quality of Care of Patients with Febrile Neutropenia
Year: 2007, type: Conference abstract
2006
-
The Use Of Lithium In The Prophylaxis And Treatment Of Chemotherapy Induced Neutropenia (CIN): A Cost-Effective Option Or Hazard
Support Care Cancer, year: 2006, volume: 2006, edition: 14